Latest Content

With evidence of antiobesity properties in human trials, berberine could be an OTC phytotherapeutic option for weight loss.

New findings reveal semaglutide 2.4 mg improves liver health in MASH patients, showing benefits beyond weight loss, as presented at The Liver Meeting 2025.

Investigators analyze COVID-19 positivity trends in NYC, revealing disparities among children and racial groups during the Omicron variant surge.

Steve Leonard, PharmD, BCIDP, joins Drug Topics on World Pneumonia Day to discuss pharmacists’ role in managing the disease.

Study findings highlight the need for further exploration into the racial and ethnic trends of pneumococcal vaccination rates.

To celebrate World Pneumonia Day, Steve Leonard, PharmD, BCIDP, joined us to discuss the variety in pneumonia types and available treatment options commonly prescribed.

Eloralintide shows promising weight loss results in a phase 2 trial, offering a new option for obesity management with improved tolerability.

In patients with diabetes and various levels of UACR, researchers aimed to uncover both the relative and absolute effects of SGLT2 inhibitors.

A study explored how SGLT2 inhibitors impact the kidney, specifically whether effects varied by estimated glomerular filtration rate (eGFR) or albuminuria.

The NCPDP gathered essential members from the pharmacy community in a roundtable discussion on electronic prior authorizations.

This episode explores the complex composition of a good leader within the pharmacy industry.

Living in the state of West Virginia for over a decade, Mark Garofoli, PharmD, BCGP, CPE, CTTS, shares his experience as a practicing pharmacist amid the US opioid crisis.

Oral semaglutide 25 mg shows significant benefits in weight loss and cardiovascular health for patients with obesity, enhancing overall well-being.

Mark Garofoli, PharmD, BCGP, CPE, CTTS, shares his pain management expertise and discusses current developments in the US opioid epidemic.

Researchers investigate women’s experiences in accessing either prescription or OTC contraceptives.

Finerenone shows promise in reducing kidney damage for type 1 diabetes patients, marking a significant advancement in chronic kidney disease treatment.

To optimize vaccine strategies among young people with Down syndrome, researchers explore the prevalence of adequate immune responses following pneumococcal vaccination.

Through diabetes education and initiatives focused on community health care, Clipper F. Young, PharmD, MPH, CDCES, BC-ADM, BCGP, is making a difference for patients and the pharmacy profession.

Older adults with dementia face significantly higher COVID-19 risks, highlighting the need for targeted health strategies during pandemics.

FDA approves lumateperone as an adjunct therapy for major depressive disorder, offering new treatment options for this indication.

A study reveals tailored glucose monitoring intervals for type 2 diabetes patients based on HbA1c levels, enhancing long-term management strategies.

Episode 4 of Wicked Good Cardiometabolic Chat explores SGLT2 inhibitors and their efficacy beyond diabetes outcomes alone.

Experts discuss the implications of the Most Favored Nation drug policy, discussing its impact on pricing, community pharmacy, and patient safety in the final part of a webinar series.

Clipper F. Young, PharmD, MPH, CDCES, BC-ADM, BCGP, discusses risks and approaches associated with severe insulin resistance among mothers and their children.

Due to humans’ physiologically premature nature, researchers explore maternal psychological distress and childhood neurodevelopment.

Pharmacy evolves from product-based to holistic care, emphasizing clinical services and patient management, driven by passionate future pharmacists.

Pharmacy professionals gather to discuss innovative solutions, fostering collaboration and community engagement at the National Community Pharmacists Association 2025 Convention & Expo.

Clipper F. Young, PharmD, MPH, CDCES, BC-ADM, BCGP, discusses the Touro University California, pharmacist-led Pharm2Home initiative.

A study reveals a significant decline in inhaled corticosteroid use among COPD patients, highlighting the need for careful management and monitoring.

Researchers explore OTC naloxone sales sold independently at pharmacies and programmatically from 2023 to 2024.

Conversations about contraceptive options have grown more frequent—and often more polarized—on social media platforms.